Washington University School of Medicine

Digital Commons@Becker
Open Access Publications

2017

Hepatocyte growth factor, a key tumor-promoting
factor in the tumor microenvironment
Benjamin Yaw Owusu
Southern Research Institute

Robert Galemmo
Protexase Therapeutics

James Janetka
Washington University School of Medicine in St. Louis

Lidija Klampfer
Southern Research Institute

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Recommended Citation
Owusu, Benjamin Yaw; Galemmo, Robert; Janetka, James; and Klampfer, Lidija, ,"Hepatocyte growth factor, a key tumor-promoting
factor in the tumor microenvironment." Cancers.9,4. 35. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5924

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

cancers
Review

Hepatocyte Growth Factor, a Key Tumor-Promoting
Factor in the Tumor Microenvironment
Benjamin Yaw Owusu 1 , Robert Galemmo 2 , James Janetka 3 and Lidija Klampfer 1, *
1
2
3

*

Department of Oncology, Drug Discovery Division, Southern Research Institute,
Birmingham, AL 35205, USA; bnyowusu@uab.edu
Protexase Therapeutics, St. Louis, MO 63110, USA; galemmo@protexase.com
Department of Biochemistry and Molecular Biophysics, Alvin J. Siteman Cancer Center,
Washington University in St. Louis, St. Louis, MO 63110, USA; janetkaj@wustl.edu
Correspondence: klampfer@southernresearch.org

Academic Editor: Jill M. Siegfried
Received: 28 February 2017; Accepted: 13 April 2017; Published: 17 April 2017

Abstract: The tumor microenvironment plays a key role in tumor development and progression.
Stromal cells secrete growth factors, cytokines and extracellular matrix proteins which promote
growth, survival and metastatic spread of cancer cells. Fibroblasts are the predominant constituent of
the tumor stroma and Hepatocyte Growth Factor (HGF), the specific ligand for the tyrosine kinase
receptor c-MET, is a major component of their secretome. Indeed, cancer-associated fibroblasts
have been shown to promote growth, survival and migration of cancer cells in an HGF-dependent
manner. Fibroblasts also confer resistance to anti-cancer therapy through HGF-induced epithelial
mesenchymal transition (EMT) and activation of pro-survival signaling pathways such as ERK and
AKT in tumor cells. Constitutive HGF/MET signaling in cancer cells is associated with increased
tumor aggressiveness and predicts poor outcome in cancer patients. Due to its role in tumor
progression and therapeutic resistance, both HGF and MET have emerged as valid therapeutic
targets. Several inhibitors of MET and HGF are currently being tested in clinical trials. Preclinical
data provide a strong indication that inhibitors of HGF/MET signaling overcome both primary and
acquired resistance to EGFR, HER2, and BRAF targeting agents. These findings support the notion
that co-targeting of cancer cells and stromal cells is required to prevent therapeutic resistance and to
increase the overall survival rate of cancer patients. HGF dependence has emerged as a hallmark of
therapeutic resistance, suggesting that inhibitors of biological activity of HGF should be included
into therapeutic regimens of cancer patients.
Keywords: HGF; tumor microenvironment; fibroblasts

1. Tumor Microenvironment
The transition from a normal to a malignant cell is driven by progressive accumulation of
mutations through which cancer cells acquire unlimited proliferative potential, resistance to apoptosis
and the ability to metastasize [1,2]. Indeed, oncogene addiction, the reliance of cancer cells on oncogenic
signaling for their survival, has been successfully utilized in targeted cancer therapy. However, tumors
are not just a mass of malignant cells, but rather resemble abnormal organs encompassing multiple
cell types, including nonmalignant cells, such as fibroblasts, immune cells, extracellular matrix (ECM),
and the vascular network [3,4] (Figure 1). It has become evident that the tumor microenvironment
plays a key role in tumor initiation, progression, metastasis and therapeutic resistance [5,6]. In fact,
cancer cells are not only addicted to specific oncogenes, but also to pro-survival signals provided by
the tumor stroma [7,8]. As such, the tumor microenvironment has emerged as an important target for
therapeutic interventions.
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Normal tissues have been shown to possess tumor-suppressing abilities, providing a barrier
Normal tissues have been shown to possess tumor-suppressing abilities, providing a
against tumorigenesis [9–11]. However, important changes occur during tumorigenesis, resulting in
barrier against tumorigenesis [9–11]. However, important changes occur during tumorigenesis,
the formation of an environment that enables tumors to progress to malignancy. These alterations
resulting in the formation of an environment that enables tumors to progress to malignancy.
are driven by tumor-derived factors and involve recruitment and activation of stromal fibroblasts,
These alterations are driven by tumor-derived factors and involve recruitment and activation of stromal
polarization and education of immune cells, matrix remodeling and the development of abnormal
fibroblasts, polarization and education of immune cells, matrix remodeling and the development
blood vasculature [12–16]. In general, factors in the tumor microenvironment tend to promote
of abnormal blood vasculature [12–16]. In general, factors in the tumor microenvironment tend
tumorigenesis, however plasticity is a principal characteristic of stromal cells, and both tumorto promote tumorigenesis, however plasticity is a principal characteristic of stromal cells, and
promoting and anti-tumorigenic properties of cancer-associated fibroblasts have been described [17,18].
both tumor-promoting and anti-tumorigenic properties of cancer-associated fibroblasts have been
Secretion of a variety of cytokines, growth factors and chemokines by stromal cells generates a
described [17,18].
pro-inflammatory microenvironment, which shares characteristics with wound healing. Indeed,
Secretion of a variety of cytokines, growth factors and chemokines by stromal cells generates
tumors have been viewed as wounds that fail to heal [19]. Accordingly, several anti-inflammatory drugs
a pro-inflammatory microenvironment, which shares characteristics with wound healing. Indeed,
have chemopreventive and therapeutic activity. For example, sulindac significantly reduces the number
tumors have been viewed as wounds that fail to heal [19]. Accordingly, several anti-inflammatory
of polyps in Familial Adenomatous Polyposis (FAP) patients who harbor a mutation in the APC gene
drugs have chemopreventive and therapeutic activity. For example, sulindac significantly reduces
[20] and the use of aspirin is associated with a better clinical outcome in colon cancer patients [21].
the number of polyps in Familial Adenomatous Polyposis (FAP) patients who harbor a mutation in
Fibroblasts and myofibroblasts are found abundant in the tumor stroma and secrete several
the APC gene [20] and the use of aspirin is associated with a better clinical outcome in colon cancer
tumor-promoting chemokines, growth factors, cytokines and extracellular matrix proteins.
patients [21].
Hepatocyte growth factor (HGF) is a major component of the fibroblast secretome [22] and cancerFibroblasts and myofibroblasts are found abundant in the tumor stroma and secrete several
associated fibroblasts have been shown to promote epithelial-mesenchymal transition, cell scattering
tumor-promoting chemokines, growth factors, cytokines and extracellular matrix proteins. Hepatocyte
and migration of cancer cells in an HGF-dependent manner. In addition, fibroblasts (or recombinant
growth factor (HGF) is a major component of the fibroblast secretome [22] and cancer-associated
HGF) promote survival of cancer cells and represent an important source of primary and acquired
fibroblasts have been shown to promote epithelial-mesenchymal transition, cell scattering and
resistance to targeted therapy, including inhibitors of EGFR (Figure 2). Finally, myofibroblasts have
migration of cancer cells in an HGF-dependent manner. In addition, fibroblasts (or recombinant
been shown to promote Wnt signalling and foster cancer stem cell phenotype by promoting Wnt
HGF) promote survival of cancer cells and represent an important source of primary and acquired
signaling through production of hepatocyte growth factor (HGF) [23].
resistance to targeted therapy, including inhibitors of EGFR (Figure 2). Finally, myofibroblasts have
been shown to promote Wnt signalling and foster cancer stem cell phenotype by promoting Wnt
signaling through production of hepatocyte growth factor (HGF) [23].
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Figure 2. Hepatocyte growth factor (HGF) or HGF-producing fibroblasts (FIB) promote epithelialFigure 2.
Hepatocyte growth factor (HGF) or HGF-producing fibroblasts (FIB) promote
mesenchymal transition (EMT), associated with inhibition of E-cadherin expression (red
epithelial-mesenchymal transition (EMT), associated with inhibition of E-cadherin expression
fluorescence), enhance cell scattering and migration, increase proliferation of cancer cells and confer
(red fluorescence), enhance cell scattering and migration, increase proliferation of cancer cells and
resistance to apoptosis. The cell migration assay shows the number of cells that migrated through the
confer resistance to apoptosis. The cell migration assay shows the number of cells that migrated
membrane of a transwell chamber. Apoptosis is shown as increased caspase-3/7 activity in gefitinib
through the membrane of a transwell chamber. Apoptosis is shown as increased caspase-3/7 activity
(GEF)-treated
colon cancercolon
cells,cancer
whichcells,
is blocked
byblocked
fibroblasts.
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from our recent publication [24].

Classification of colon cancer patients based on distinct global gene expression profiles has been
Classification of colon cancer patients based on distinct global gene expression profiles has been
shown to have prognostic and predictive significance [25–27]. According to this classification,
shown to have prognostic and predictive significance [25–27]. According to this classification, patients
patients with cancers characterized by the stemness/serrated/mesenchymal (SSM) gene signature
with cancers characterized by the stemness/serrated/mesenchymal (SSM) gene signature have a poor
have a poor prognosis. However, careful analysis of these classification systems by Calon et al.
prognosis. However, careful analysis of these classification systems by Calon et al. established that
established that the predictive power of this gene signature is derived from gene expression in
the predictive power of this gene signature is derived from gene expression in stromal rather than in
stromal rather than in epithelial cells [28]. The authors demonstrated that TGF-β signaling in cancerepithelial cells [28]. The authors demonstrated that TGF-β signaling in cancer- associated fibroblasts
associated fibroblasts (CAFs) increased the frequency of tumor-initiating cells, a common feature of
(CAFs) increased the frequency of tumor-initiating cells, a common feature of all colorectal cancer
all colorectal cancer subtypes with poor prognosis. Accordingly, pharmacological inhibition of TGFsubtypes with poor prognosis. Accordingly, pharmacological inhibition of TGF-β signaling blocked
β signaling blocked the crosstalk between cancer cells and fibroblasts and prevented metastatic
the crosstalk between cancer cells and fibroblasts and prevented metastatic spread [28]. Another group
spread [28]. Another group confirmed that the CAF signature was associated with poor prognosis in
confirmed that the CAF signature was associated with poor prognosis in untreated colon cancer
untreated colon cancer patients and predicted resistance to radiotherapy in rectal cancer [29]. These
patients and predicted resistance to radiotherapy in rectal cancer [29]. These studies confirmed
studies confirmed that stroma significantly contributes to clinical features of colorectal cancer and
that stroma significantly contributes to clinical features of colorectal cancer and shapes the response
shapes
the response to therapy.
to therapy.
Thus, it is becoming clear that drugs which would normalize the tumor stroma or would block
Thus,between
it is becoming
drugs
which
would
normalize theinto
tumor
stroma orregimens
would block
signaling
stromaclear
andthat
tumor
cells
should
be incorporated
therapeutic
for
signaling
between
stroma
and
tumor
cells
should
be
incorporated
into
therapeutic
regimens
cancer
cancer patients in order to control cancer spread and/or to prevent cancer recurrence. Tumorfor
cells
are
patients
order
to control cancer
and/or tochanges
prevent pose
cancer
recurrence.
Tumor
are
dynamic,inand
ever-evolving
geneticspread
and epigenetic
a serious
challenge
forcells
cancer
dynamic, In
andcontrast,
ever-evolving
genetic
and epigenetic
changes pose
challenge
cancer
therapy.
cells in
the tumor
microenvironment
area serious
genetically
stablefor
and
the therapy.
tumorIn
contrast,
cells
in
the
tumor
microenvironment
are
genetically
stable
and
the
tumor-promoting
promoting nature of the tumor microenvironment is reversible, suggesting that the nature
tumor
microenvironment may be a preferred target for therapeutic approaches.

Cancers 2017, 9, 35

4 of 16

of the tumor microenvironment is reversible, suggesting that the tumor microenvironment may be a
preferred
Cancers 2017,target
9, 35 for therapeutic approaches.
4 of 15
2.
2. HGF/MET
HGF/MET Signaling
Signaling in
in the
the Tumor
Tumor Microenvironment
Microenvironment
HGF
has been
been identified
identifiedas
asaascattering
scatteringfactor
factorfor
forepithelial
epithelial
cells
[30–32]
and,
independently,
HGF has
cells
[30–32]
and,
independently,
as
as
a
fibroblast-secreted
factor
that
promotes
the
motility
of
epithelial
cells
[33].
Binding
of HGF
to
a fibroblast-secreted factor that promotes the motility of epithelial cells [33]. Binding of HGF
to its
its
receptor,
MET,
leads
receptordimerization
dimerizationand
andinduction
inductionof
of signaling
signaling pathways
pathways that
receptor,
MET,
leads
totoreceptor
that support
support
growth,
survival,
motility
and
metastatic
spread
of
cancer
cells.
Although
HGF
is
the
sole
ligand
growth, survival, motility and metastatic spread of cancer cells. Although HGF is the sole ligand
for
for
MET,
growth
factors
as EGF
TGFα
shown
to induce
delayed
activation
of
MET,
growth
factors
suchsuch
as EGF
and and
TGFα
havehave
beenbeen
shown
to induce
delayed
activation
of MET,
MET,
which
depends
on
the
EGFR
kinase
activity
[34].
In
fact,
the
crosstalk
between
EGFR
and
MET
which depends on the EGFR kinase activity [34]. In fact, the crosstalk between EGFR and MET
maximizes
maximizes the
the oncogenic
oncogenic activity
activity of
of EGFR
EGFR and
and leads
leads to
to increased
increased migration
migration and
and invasion
invasion of
of lung
lung
cancer
cancer cells
cells [34].
[34].
MET
activation and
and STAT3
STAT3 signaling,
MET activation
activation triggers
triggers Ras-dependent
Ras-dependent ERK1/ERK2
ERK1/ERK2 activation
signaling, which
which
contribute
to
enhanced
proliferation,
survival
and
migration
of
cancer
cells
(Figure
3).
contribute to enhanced proliferation, survival and migration of cancer cells (Figure 3). HGF-induced
HGF-induced
MET
multiple pro-survival
pro-survival pathways
pathways in
in cancer
cancer cells,
cells, such
such as
as AKT
AKT and
andSTAT3,
STAT3,
MET activation
activation also
also triggers
triggers multiple
promotes
epithelial-mesenchymal
transition
(EMT),
and
thus
confers
primary
and
acquired
resistance
promotes epithelial-mesenchymal transition (EMT), and thus confers primary and acquired
to
anti-cancer
therapy [35–39].
resistance
to anti-cancer
therapy [35–39].

Figure 3.
3. HGF/MET
HGF/MET signaling.
that result
result in
in
Figure
signaling. Binding
Binding of
of HGF
HGF to
to MET
MET induces
induces conformational
conformational changes
changes that
receptor
dimerization
and
trans-phosphorylation
of
tyrosine
residues
in
the
catalytic
domain
of
MET
receptor dimerization and trans-phosphorylation of tyrosine residues in the catalytic domain of MET
and phosphorylation
phosphorylation of
of tyrosine
tyrosine residues
residues in
in the
the carboxyl-terminal
carboxyl-terminal tail.
tail. The
The phosphorylated
phosphorylated tyrosine
tyrosine
and
residues create
create docking
docking sites
sites for
for several
several adaptor
adaptor molecules
molecules and
and kinase
kinase substrates
substrates as
as indicated.
indicated. MET
MET
residues
activation
leads
to
subsequent
activation
of
signaling
pathways
that
include
MAPK,
PI3K/AKT
and
activation leads to subsequent activation of signaling pathways that include MAPK, PI3K/AKT and
STAT3,
which
mediate
MET-dependent
cell
proliferation,
survival,
migration
and
invasion.
STAT3, which mediate MET-dependent cell proliferation, survival, migration and invasion.

HGF/MET signaling plays a crucial role in embryogenesis, organogenesis, wound healing and
tissue repair, at least in part by stimulating epithelial to mesenchymal transition (EMT). Indeed, HGF
or MET deficiency in mice is embryonically lethal. However, constitutive activation of the HGF/MET
signaling pathway promotes the growth and survival of cancer cells and stimulates their metastatic
spread [40]. Accordingly, activation of the HGF/MET signaling pathway in tumor cells is associated
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HGF/MET signaling plays a crucial role in embryogenesis, organogenesis, wound healing and
tissue repair, at least in part by stimulating epithelial to mesenchymal transition (EMT). Indeed, HGF
or MET deficiency in mice is embryonically lethal. However, constitutive activation of the HGF/MET
signaling pathway promotes the growth and survival of cancer cells and stimulates their metastatic
spread [40]. Accordingly, activation of the HGF/MET signaling pathway in tumor cells is associated
with tumor aggressiveness and resistance to therapy, and predicts poor outcome in cancers patients [41].
Colon cancer patients, particularly patients with lymph node and liver metastasis, have increased
levels of HGF in serum and in tumor tissues [42]. Elevated levels of HGF are associated with poor
survival of stage II and stage III colon cancer patients [43]. High levels of HGF also correlate with
lymph node metastasis and relapse in breast cancer patients [44,45], multiple myeloma patients [46]
and myeloid leukemia patients [47].
Cancers 2017, 9, 35
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Figure 4. HGF-dependent and HGF-independent MET activation. Cancer cells can produce pro-HGF
Figure 4. HGF-dependent and HGF-independent MET activation. Cancer cells can produce pro-HGF
(due to mutations in the HGF promoter or expression of oncogenic transcription factors), which
(due to mutations in the HGF promoter or expression of oncogenic transcription factors), which
activates MET in an autocrine manner. More commonly, pro-HGF is produced by stromal cells, such
activates MET in an autocrine manner. More commonly, pro-HGF is produced by stromal cells, such as
as fibroblasts, and HGF activates MET in a paracrine manner. Ligand-independent MET activation
fibroblasts, and HGF activates MET in a paracrine manner. Ligand-independent MET activation occurs
occurs due to overexpression or amplification of MET or due to mutational activation of MET.
due to overexpression or amplification of MET or due to mutational activation of MET.

3. HGF/MET Signaling Is a Hallmark of Therapeutic Resistance
In general, autocrine production of HGF by cancer cells occurs infrequently. More commonly
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inhibition of MET prevented the tumor-promoting activity of IKKβ-deficient fibroblasts, confirming
targeted treatment of cancer. Factors in the tumor microenvironment, including HGF, promote tumor
heterogeneity, at least in part, by providing an appropriate niche for cancer stem cells (CSC) [89,90].
Only a small population of patients respond to targeted therapy (de novo resistance), and patients
that initially show a dramatic response to therapy develop resistance within months (acquired
resistance). This limits the efficiency of targeted therapeutic approaches and results in local or systemic
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the significance of HGF/MET signaling for the crosstalk between cancer cells and tumor-promoting
fibroblasts. Targeted deletion of epimorphin, which decreased expression of HGF in myofibroblasts,
reduces polyposis in ApcMin/+ mice, indicating that epimorphin exerts oncogenic potential via
remodeling of the stromal microenvironment [57]. Tumor progression locus 2 (TPL2) deficiency
leads to increased HGF expression in intestinal fibroblasts, coupled to increased MET activation in
epithelial cells [58]. TPL2 has been recently shown to have tumor suppressor properties in the ApcMin/+
model [59].
However, regardless of its cellular origin, HGF is always secreted as pro-HGF, an inactive
precursor. While capable of binding to MET, pro-HGF does not trigger MET activation, and therefore
acts as a receptor antagonist. A proteolytically inert mutant of pro-HGF confirmed the competitive
antagonism between HGF and pro-HGF, and suppressed proliferation, motility and invasiveness of
cancer cells in vitro and inhibited tumor growth and metastases in vivo [60]. Proteolytic conversion of
pro-HGF to its active form is the rate-limiting step in the HGF/MET signaling pathway. The trypsin-like
serine proteases, matriptase, hepsin and HGF activator (HGFA), which are commonly over-expressed
in tumor cells, are three principal proteases responsible for HGF activation [61–68]. These enzymes
cleave pro-HGF to HGF 102 –104 times more efficiently than, for example, TMPRSS13 (Transmembrane
Protease, Serine 13) or uPA (urokinase plasminogen activator) [68,69]. The activity of matriptase,
HGFA and hepsin is controlled by the endogenous inhibitors of pro-HGF activation, the HGFA
inhibitors (HAI)-1/2 [68,70,71], whose expression is reduced in tumor tissues. Intestinal deletion of
endogenous HAI-1 augments Wnt signaling in ApcMin/+ mice, both in tumors and in normal mucosa,
and enhances intestinal tumor formation [72], confirming that HAI-1 has tumor suppressor properties.
Accordingly, reduced expression of HAIs is associated with advanced disease and poor outcome in
cancer patients [72–78]. Small molecule inhibitors of HGFA and antibodies neutralizing HGFA and
matriptase have been developed [79] as potential therapeutic agents. However, we developed the first
small molecule triplex inhibitors of HGFA, matriptase and hepsin [80–82], and confirmed that they
block oncogenic HGF/MET signaling [24].
MET mutations, MET amplifications or MET overexpression, which trigger ligand-independent
activation of MET signaling (Figure 4), are rare in primary human cancer [53]. MET activating
mutations in cancer have been described in renal papillary carcinomas, hepatocellular carcinomas [83],
small-cell lung cancer and colon cancers [84]. However, MET mutations are frequently detected in
metastatic disease and increased expression/amplification of MET in colorectal cancer patients has
been shown to promote the metastatic spread of cancer [85]. Recently it has been established that
MET-positive breast cancer cells, such as triple negative breast cancer, preferentially metastasize to
the brain via induction of IL-1β. MET-induced IL-1β triggers pro-HGF secretion in tumor-associated
astrocytes, establishing a pro-metastatic inflammatory tumor microenvironment [86].
In addition, MET amplifications were detected in a significant number of lung- and colon cancer
patients with acquired resistance to anti-EGFR therapy [87,88] (see below). While MET-amplified
cancer cells do not respond to EGFR-targeting drugs, they are uniquely sensitive to anti-MET therapy.
3. HGF/MET Signaling Is a Hallmark of Therapeutic Resistance
Conventional cancer therapy, including chemotherapy and radiation, does not distinguish
between normal and cancer cells. In contrast, targeted therapeutic agents, which block individual
pathways that cancer cells are addicted to (such as EGFR, BRAF, MET or HER2 signaling), are specific
for cancer cells and have potentially fewer side effects. However, tumors are extremely heterogeneous
and cancer cells within a single tumor show extensive genetic, epigenetic and metabolic differences.
Such differences have important consequences for the diagnosis and the targeted treatment of cancer.
Factors in the tumor microenvironment, including HGF, promote tumor heterogeneity, at least in part,
by providing an appropriate niche for cancer stem cells (CSC) [89,90].
Only a small population of patients respond to targeted therapy (de novo resistance), and patients
that initially show a dramatic response to therapy develop resistance within months (acquired resistance).
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This limits the efficiency of targeted therapeutic approaches and results in local or systemic cancer
recurrence. Therapeutic resistance is indeed the major cause of failure in curing cancer patients.
One of the ten recommendations of the Blue Ribbon Panel to achieve the Cancer Moonshot goal
was to “Identify therapeutic targets to overcome drug resistance through studies that determine the
mechanisms that lead cancer cells to become resistant to previously effective treatments”.
Resistance to therapy can develop due to genetic changes in cancer cells that confer a therapy
resistant phenotype. For example, mutations in the KRAS gene are associated with resistance to
anti-EGFR drugs, which are approved selectively for colon cancer patients with wild type (WT) KRAS.
In addition, the tumor microenvironment is a frequent source of resistance to therapy. HGF has been
identified as a factor in the tumor microenvironment that blocks the response to cancer therapy. MET
activation has been shown to underlie the resistance to drugs targeting EGFR, FGFR, BRAF, VEGF and
HER2, demonstrating that MET activation is a general feature of resistance to targeted therapy [38,91].
Among proposed predictive biomarkers for HGF/MET targeting are determination of MET expression
by immunohistochemistry, MET copy number changes and monitoring the levels of MET and HGF in
plasma. However, none of these biomarkers have been vigorously tested in cancer patients.
How does HGF inhibit the response to therapy? HGF promotes epithelial mesenchymal transition
(EMT) (Figure 2) which is likely to contribute to its ability to confer resistance to therapeutic approaches.
It has been demonstrated that cells that underwent EMT are more resistant to cell death and display
resistance to therapy [92,93]. Accordingly, decreased expression of E-cadherin, a hallmark of the
mesenchymal phenotype, is associated with resistance to inhibitors of EGFR [94]. HGF promotes EMT
by inducing the expression of EMT-associated transcription factors, including Snail1 [95] and Zeb1 [96].
We and others have demonstrated that Snail is sufficient to protect cancer cells from apoptosis [97–99].
Snail confers resistance to classical chemotherapy, but also to immunotherapy [100] and targeted
therapy [101,102].
Finally, EMT promotes acquisition of a stem cell phenotype, generating cells that are extremely
resistant to therapy. Activation of anti-apoptotic signaling pathways, such as Wnt and Notch, and
proliferative/metabolic quiescence contribute to the drug-resistant phenotype of cancer stem cells
(CSCs). Indeed, myofibroblast-derived HGF has been shown to induce Wnt signaling in colon cancer
cells and to confer the cancer stem cell phenotype in vitro and in vivo [23]. MET activation also
promotes the cancer stem cell phenotype in several other types of cancer, including gliomas [103,104],
colon cancer [55], head and neck cancer [105], prostate cancer [106] and pancreatic cancer [107].
We demonstrated that HGF or HGF-producing fibroblasts conferred resistance to EGFR targeting
therapy by reactivation of pro-survival pathways in cancer cells, including ERK and AKT activation [24].
Inhibition of the MET kinase activity by JNJ38877605 or inhibition of the biological activity of
HGF by SRI31215, a novel small molecule inhibitor of pro-HGF activation, restored sensitivity of
HGF-producing colon cancer cells to EGFR inhibition by blocking autocrine MET activation. SRI31215
or JNJ38877605 also overcame resistance mediated by HGF-producing fibroblasts, demonstrating that
inhibition of HGF/MET signaling prevents tumor-microenvironment-mediated resistance to targeted
therapy (Figure 5). Co-inhibition of EGFR and MET promotes eradication of colon cancer stem cells,
resulting in durable tumor regression [55].
Consistent with preclinical studies, increased levels of HGF in colon cancer patients with WT
KRAS, and in NSCLC patients correlate with lack of response to EGFR inhibitors [108,109].
EGFR targeting drugs have also significantly improved the outcome of lung cancer patients.
Most NSCLC patients with EGFR mutations initially respond to treatment with EGFR tyrosine kinase
inhibitors (TKI), but resistance develops rapidly in virtually all patients. Acquired resistance to EGFR
inhibitors has been associated frequently with selection for secondary EGFR mutations, such as T790M
in exon 20 [110,111], or with MET amplifications [112]. Most troublingly, MET amplification confers
resistance to first- and third-generation of EGFR inhibitors.
MET-amplified lung cancers are addicted to MET signaling and are therefore extremely sensitive to
MET inhibition [113]. Several MET TKI and MET specific antibodies have entered clinical trials [79,114].

Cancers 2017, 9, 35

8 of 16

However, based on preclinical data, acquired resistance to MET kinase inhibitors is likely to occur
rapidly in cancer patients as well. Moreover, it has been shown that acquired resistance to kinase
inhibitors, which prompts discontinuation of this therapy, is associated with accelerated disease
progression. MET kinase inhibitors block MET endocytosis, resulting in an increased number of cell
surface receptors and subsequent re-activation of MET signaling [115]. In some cases, a switch to EGFR
dependency has been shown to underlie the resistance to MET kinase inhibitors [116,117]. However,
some lung cancer cells fail to respond to combined treatment with EGFR and MET inhibitors or develop
resistance to dual EGFR/MET inhibition [118]. Thus, novel therapeutic targets and rationally designed
combination therapies are needed to enhance the initial response to therapy and to overcome acquired
therapeutic
Cancers 2017, 9,resistance.
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Owusu et al. [119] and others [35] have demonstrated that HGF drives resistance to anti-MET
Owusu et al. [119] and others [35] have demonstrated that HGF drives resistance to anti-MET
therapy in MET-amplified lung cancer cells (Figure 6), revealing that MET-amplified NSCLC cells
therapy in MET-amplified lung cancer cells (Figure 6), revealing that MET-amplified NSCLC cells
become addicted to HGF upon MET inhibition. HGF or pro-HGF-producing fibroblasts inhibit not
become addicted to HGF upon MET inhibition. HGF or pro-HGF-producing fibroblasts inhibit not
only the response to individual treatment with a MET kinase inhibitor, but also the response to dual
only the response to individual treatment with a MET kinase inhibitor, but also the response to
inhibition of EGFR and MET [119]. We demonstrated that HGF reactivates MET, EGFR and RON
dual inhibition of EGFR and MET [119]. We demonstrated that HGF reactivates MET, EGFR and
signaling and restores AKT, ERK and WNK1 activation in MET-inhibited cells. Thus, upfront
RON signaling and restores AKT, ERK and WNK1 activation in MET-inhibited cells. Thus, upfront
inhibition of HGF and MET, or triple inhibition of EGFR, MET and HGF, may be required to prevent
inhibition of HGF and MET, or triple inhibition of EGFR, MET and HGF, may be required to prevent
the development of resistance to targeted therapy in MET-amplified NSCLC cells. Supporting this
the development of resistance to targeted therapy in MET-amplified NSCLC cells. Supporting this
notion, it has been shown that HGF is required for optimal activation of the MET kinase in MET
amplified cancer cells [120].
We demonstrated that SRI31215, an inhibitor of pro-HGF activation, blocked crosstalk between
tumor cells and fibroblasts in MET-amplified NSCLC cells. SRI31215 overcame fibroblast-mediated
resistance to MET inhibition or to dual MET/EGFR inhibition by preventing fibroblast-mediated
reactivation of AKT and ERK signaling. Structurally-unrelated triplex inhibitors of pro-HGF
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4. Conclusions
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Moreover, we and others have demonstrated that inhibition of both MET and HGF is required to
overcome therapeutic resistance in MET-amplified cancer cells. We developed the first small molecule
inhibitorsofofInterest:
pro-HGF
activation
and demonstrated
that they efficiently block HGF/MET signaling and
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overcome HGF-mediated resistance to targeted therapy. Thus, agents blocking the biological activity
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